Abstract
A prospective randomised study was carried out to compare the effect of mesna (2-mercaptoethane sulphonate sodium) with that of forced diuresis in preventing cyclophosphamide induced haemorrhagic cystitis in marrow transplant recipients. Sixty-one consecutive BMT recipients were randomised for treatment with forced diuresis or mesna. The incidence of macroscopic haematuria was significantly lower in the mesna treated group (chi 2 = 4.03, P less than 0.05). No specific side effects of mesna were detected. The lymphopenia induced by cyclophosphamide in the aplastic recipients was similar in the mesna and forced diuresis groups suggesting that mesna has no effect on the lymphocytotoxic activity of cyclophosphamide, although 6 out of 7 episodes of graft failure documented in the study occurred in mesna treated patients. As a result of this study our present policy is to use mesna in all BMT recipients but to continue careful documentation of the incidence of graft failure.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brock N., Pohl J., Stekar J. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. J Cancer Res Clin Oncol. 1981;100(3):311–320. doi: 10.1007/BF00410691. [DOI] [PubMed] [Google Scholar]
- Brock N., Stekar J., Pohl J., Niemeyer U., Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung. 1979;29(4):659–661. [PubMed] [Google Scholar]
- Bryant B. M., Jarman M., Ford H. T., Smith I. E. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet. 1980 Sep 27;2(8196):657–659. doi: 10.1016/s0140-6736(80)92703-8. [DOI] [PubMed] [Google Scholar]
- Camitta B. M., Thomas E. D., Nathan D. G., Santos G., Gordon-Smith E. C., Gale R. P., Rappeport J. M., Storb R. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976 Jul;48(1):63–70. [PubMed] [Google Scholar]
- Cox P. J. Cyclophosphamide cystitis--identification of acrolein as the causative agent. Biochem Pharmacol. 1979 Jul 1;28(13):2045–2049. doi: 10.1016/0006-2952(79)90222-3. [DOI] [PubMed] [Google Scholar]
- GEORGE P. HAEMORRHAGIC CYSTITIS AND CYCLOPHOSPHAMIDE. Lancet. 1963 Nov 2;2(7314):942–942. doi: 10.1016/s0140-6736(63)90653-6. [DOI] [PubMed] [Google Scholar]
- Glucksberg H., Storb R., Fefer A., Buckner C. D., Neiman P. E., Clift R. A., Lerner K. G., Thomas E. D. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974 Oct;18(4):295–304. doi: 10.1097/00007890-197410000-00001. [DOI] [PubMed] [Google Scholar]
- Hows J. M., Chipping P. M., Fairhead S., Smith J., Baughan A., Gordon-Smith E. C. Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A. Br J Haematol. 1983 May;54(1):69–78. doi: 10.1111/j.1365-2141.1983.tb02068.x. [DOI] [PubMed] [Google Scholar]
- Hows J. M., Palmer S., Gordon-Smith E. C. Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia. Transplantation. 1982 Apr;33(4):382–386. doi: 10.1097/00007890-198204000-00008. [DOI] [PubMed] [Google Scholar]
- Link H., Neef V., Niethammer D., Wilms K. Prophylaxis of haemorrhagic cystitis due to cyclophosphamide-conditioning for bone marrow transplantation. Blut. 1981 Nov;43(5):329–330. doi: 10.1007/BF00320957. [DOI] [PubMed] [Google Scholar]
- Storb R., Thomas E. D., Weiden P. L., Buckner C. D., Clift R. A., Fefer A., Fernando L. P., Giblett E. R., Goodell B. W., Johnson F. L. Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood. 1976 Dec;48(6):817–841. [PubMed] [Google Scholar]